Renalytix AI Challenges Nasdaq Delisting
Company Announcements

Renalytix AI Challenges Nasdaq Delisting

Renalytix AI (GB:RENX) has released an update.

Renalytix AI has submitted a hearing request to the Nasdaq Hearings Panel to address its delisting due to non-compliance with market value and minimum bid price requirements. The company’s American Depositary Shares will continue trading on The Nasdaq Global Market under the symbol ‘RNLX’ until the Panel’s decision is made. Renalytix AI’s plan to regain compliance will be presented at the hearing, but there is no guarantee of its acceptance or the company’s ability to meet Nasdaq’s listing criteria moving forward.

For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskRenalytix AI Reduces Debt with New Share Issue
TheFlyRenalytix announces collaboration with Steno Diabetes Center
GlobeNewswireRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!